Werewolf Therapeutics details cancer pipeline progress, shares watched by biotech investors

Werewolf Therapeutics is working on conditionally activated cancer immunotherapies and continues to advance its WTX-124 and WTX-330 programs, while its Nasdaq-listed shares draw interest from biotech-focused investors.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 19:44.

Werewolf Therapeutics (US4433141076) develops conditionally activated immunotherapies for cancer patients. The clinical-stage biotech, whose HOWL ticker trades on the Nasdaq, continues to advance its interleukin-2 and interleukin-12 INDUKINE programs alongside other early pipeline assets.

Clinical-stage biotech with INDUKINE platform

Werewolf Therapeutics focuses on so-called INDUKINE molecules, which are designed to remain inactive in healthy tissue and become activated only in the tumor microenvironment, aiming to widen the therapeutic window for potent cytokines such as IL-2 and IL-12.

The company positions itself within the competitive oncology immunotherapy space alongside peers like Iovance Biotherapeutics and Immunocore, targeting solid tumors with next-generation immune-modulating agents rather than classic chemotherapy or small-molecule approaches.

Pipeline built around WTX-124 and WTX-330

Lead candidate WTX-124 is a conditionally activated IL-2 INDUKINE molecule that Werewolf Therapeutics is developing for advanced solid tumors, with early-stage clinical evaluation focused on safety, tolerability, and preliminary signs of anti-tumor activity.

WTX-330, an IL-12 INDUKINE molecule, is another key program intended to harness the pro-inflammatory and immune-activating properties of interleukin-12 while controlling systemic exposure through tumor-selective activation.

The product behind the stock

Werewolf Therapeutics generates its potential future revenue primarily from its experimental INDUKINE candidates such as WTX-124 and WTX-330, which are designed to be activated predominantly in tumors so that systemic cytokine exposure can be limited while maintaining strong local immune stimulation.

Where the stock trades today

Werewolf Therapeutics shares trade on the Nasdaq in U.S. dollars under the HOWL ticker; recent quotes place the company firmly within the small-cap U.S. biotech universe.

Werewolf Therapeutics at a glance

• Company: Werewolf Therapeutics, Inc.
• ISIN: US4433141076
• WKN: A3CM5J
• Ticker: HOWL
• Trading venue: Nasdaq
• Price (as of 2026-06-26, 17:30): 1.85 USD
• Market cap: 80,000,000 USD (as of 2026-06-26)
• Sector / industry: Biotechnology / Oncology
• Index membership: not a member of major benchmark indices
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.